Silverback Therapeutics raises $78.5m in oversubscribed Series B financing

Silverback Therapeutics (“Silverback”) (“the Company”), a private biopharmaceutical company pioneering a new class of immune-modulating ImmunoTAC drug conjugates targeting previously inaccessible disease pathways, today announced the close of an oversubscribed $78.5 million Series B financing round.